Use of botulinum toxin A in pelvic floor dysfunctions in the elderly: A review. Intérêt de la toxine botulinique A dans le traitement des troubles pelvi-périnéaux de la personne âgée

Archive ouverte

Biardeau, X. | Haddad, R. | Chesnel, C. | Charlanes, A. | Hentzen, C. | Turmel, N. | Campagne, S. | Capon, G. | Fatton, B. | Gamé, X. | Jeandel, C. | Kerdraon, J. | Mares, P. | Mezzadri, M. | Petit, A.-C. | Peyronnet, B. | Soler, J.-M. | Thuillier, C. | Deffieux, X. | Robain, G. | Amarenco, G. | Manceau, P.

Edité par CCSD ; Elsevier Masson -

International audience. The present article is the final report of a multi-disciplinary meeting supported by the GRAPPPA (group for research applied to pelvic floor dysfunctions in the elderly). The objective was to conduct a comprehensive review on the role of botulinum toxin A (BonTA) in the treatment of pelvic floor dysfunctions in the elderly.Methods: The present article, written as a comprehensive review of the literature, combines data issued from the scientific literature with expert's opinions. Review of the literature was performed using the online bibliographic database MedLine (National Library of Medicine). Regarding intra-detrusor BonTA injections, only articles focusing on elderly patients (>65 yo) were included. Regarding other localizations, given the limited number of data, all articles reporting outcomes of BonTA were included, regardless of studies population age. In case of missing or insufficient data, expert's opinions were formulated.Results: Although, available data are lacking in this specific population, it appears that BonTA could be used in the non-fraily elderly patients to treat overactive bladder or even neurogenic detrusor overactivity, with a success rate comparable to younger population at 3 months (88.9% vs. 91.2%), 6 months (49.4% vs. 52.1%) and 12 months (23.1% vs. 22.3%), as well as a significant decrease in number of voids per day (11.4 vs. 5.29 P<0.001) and in the number of pads per day (4.0 vs. 1.3, P<0.01). Furthermore, BonTA is likely to be offered in the future as a treatment of fecal incontinence and obstructed defecation syndrome symptoms. Concerning bladder outlet obstruction/voiding dysfunction symptoms, intra-urethral sphincter BonTA should not be recommended.Conclusion: BonTA injections are of interest in the management of various pelvic floor dysfunctions in the elderly, and its various applications should be better evaluated in this specific population in order to further determine its safety and efficacy.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion